Clinical trials: SGLT 2 Inhibitors
Type 1 Diabetes, Nephropathy, Diabetic
SGLT2 Adjunct in T1D
Effect of Sodium-Glucose Cotransporter (SGLT) 2 Inhibitors on Diabetic Nephropathy Progression in Adolescents with Type 1 Diabetes Mellitus
- Trial name
- NCT07591077
- Testing
- Empagliflozin (EMPA)
- Where
- Egypt
- Volunteers
- 86 people
- Sponsor
- Ain Shams University
Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain
Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial
The goal of this clinical trial is to learn whether dapagliflozin can help manage weight gain caused by antipsychotic medications in people aged 16 years or older who are receiving antipsychotic treatment and have developed…
- Trial name
- NCT07342764
- Testing
- Dapagliflozin, Metformin, Common Lifestyle Program
- Where
- Oman
- Volunteers
- 110 people
- Sponsor
- Sultan Qaboos University
Diabetes Mellitus, Type 2
Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to integrate the post-marketing surveillances data (Specified use-results surveys on long-term treatment) of the 6 SGLT2 inhibitors approved or applied in Japan and to evaluate the safety and efficacy…
- Trial name
- NCT02284269
- Testing
- SGLT2 Inhibitors
- Volunteers
- 18,000 people
- Sponsor
- Pharmaceuticals and Medical Devices Agency, Japan
Type2 Diabetes
Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal Insulin
The change of glycemic variation and insulin dose after adding SGLT2 inhibitor in type 2 diabetic patients treated with basal insulin was observed in a single center.
- Trial name
- NCT03631134
- Testing
- SGLT2 inhibitor
- Volunteers
- 100 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Fontan, Heart Failure
The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure
While the Fontan operation improves survival for patients with a functional single ventricle, complications like heart failure remain prevalent during follow-up, causing frequent hospitalizations and reduced quality of life.
- Conditions
- Fontan, Heart Failure, Dapagliflozin, Cardiovascular Diseases
- Trial name
- NCT07482943
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
- Where
- 2 sites in Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Breast Cancer
Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
Background: Breast cancer is the most frequently diagnosed malignancy among women worldwide and a major cause of morbidity and mortality.
- Trial name
- SGLT2i/DPPi (NCT07436663)
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy, Sitagliptin (DPP4 inhibitor), Standard Care (in control arm)
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tanta University
Lung Cancer
SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes
The goal of this clinical trial The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and…
- Trial name
- NCT07272057
- Testing
- SGLT-2 inhibitor
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
Diabetic Nephropathies, Diabetes Mellitus, Type 2
Comparing The Effect Of Empagliflozin With Dapagliflozin In Reducing Proteinuria In Diabetic Patients With Chronic Kidney Disease With eGFR More Than 45ml/Min/1.73m²
This study was designed to compare empagliflozin and dapagliflozin in reducing protein leakage into the urine in adults with type 2 diabetes and chronic kidney disease.
- Conditions
- Diabetic Nephropathies, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
- Trial name
- NCT07866235
- Testing
- Dapagliflozin, Empagliflozin (EMPA)
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- Lahore General Hospital
Chronic Kidney Disease
Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with…
- Trial name
- NCT07348484
- Testing
- Empagliflozin
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Perioperative Complication
SGLT2 Inhibitors and Perioperative Period
The expanded use of SGLT2 inhibitors motivates us to assess the role of SGLT2 inhibitors in perioperative period on patients who will undergo cardiac surgery in Assiut University.
- Trial name
- NCT06326528
- Testing
- SGLT2 inhibitor
- Volunteers
- 100 people
- Sponsor
- Assiut University
Duchenne Muscular Dystrophy (DMD)
Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
This is a pharmacokinetic study (PK Study) to better understand empagliflozin dosing in pediatric Duchenne muscular dystrophy patients.
- Trial name
- CHERISH (NCT07172971)
- Testing
- SGLT-2 inhibitor, SGLT2 inhibitor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt University Medical Center
SLE, Lupus Nephritis
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
This study aims to assess sodium glucose linked transoprter inhibitors(SGT2i) role in regression of ongoing kidney and cardiac diseases among lupus nephritis patient either diabetic or non-diabetic under different…
- Conditions
- SLE, Lupus Nephritis, SGLT2 Inhibitors
- Trial name
- NCT05748925
- Testing
- dapagliflozin
- Where
- Egypt
- Volunteers
- 84 people
- Sponsor
- Mansoura University
Diabetes Mellitus Type 2
Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus evaluating the comparative effectiveness of initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus…
- Trial name
- CVD-REAL (NCT02993614)
- Where
- 17 sites in United States, Australia and 15 more
- Volunteers
- 99,999 people
- Sponsor
- AstraZeneca
Non-Alcoholic Fatty Liver Disease, NAFLD
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Conditions
- Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
- Trial name
- SLIDE (NCT03867487)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Justin Ryder
SGLT 2 Inhibitors, Pediatric Kidney Disease
Efficacy and Safety of Dapagliflozin in Children With Proteinuria
This interventional study investigates the efficacy of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in pediatric patients with renal disease.
- Conditions
- SGLT 2 Inhibitors, Pediatric Kidney Disease, Proteinuric Diseases, Dapagliflozin (Forxiga)
- Trial name
- NCT07204743
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
- Where
- Palestinian Territories
- Volunteers
- 10 people
- Sponsor
- Al-Quds University
Type 2 Diabetes
Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients
The objective of this survey is to confirm the safety of Suglat Tablets
- Trial name
- STELLALONGTERM (NCT02479399)
- Testing
- ipragliflozin
- Where
- 8 sites in Japan
- Volunteers
- 11,412 people
- Sponsor
- Astellas Pharma Inc
End Stage Chronic Renal Failure
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis.
- Trial name
- NCT07491042
- Testing
- Dapagliflozin
- Where
- Oman
- Volunteers
- 38 people
- Sponsor
- Oman Ministry of Health